Identification of Wee1 as a novel therapeutic target for mutant RAS-driven acute leukemia and other malignancies

Leukemia

Volumn 29, Issue 1, 2015, Pages 27-37

  Weisberg, E ^a   Nonami, A ^a   Chen, Z ^a   Liu, F ^b   Zhang, J ^a   Sattler, M ^a   Nelson, E ^a   Cowens, K ^a   Christie, A L ^a   Mitsiades, C ^a   Wong, K K ^a   Liu, Q ^b   Gray, N ^a   Griffin, J D ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

Author keywords

[No Author keywords available]

Indexed keywords

2 ALLYL 1 [6 (1 HYDROXY 1 METHYLETHYL) 2 PYRIDINYL] 6 [4 (4 METHYL 1 PIPERAZINYL)ANILINO] 1H PYRAZOLO[3,4 D]PYRIMIDIN 3(2H) ONE; CYCLIN DEPENDENT KINASE 1; INITIATION FACTOR 4E BINDING PROTEIN 1; K RAS PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE; PROTEIN KINASE B; RAS PROTEIN; S6 KINASE; TORIN 2; UNCLASSIFIED DRUG; WEE1 KINASE; ANTINEOPLASTIC AGENT; CELL CYCLE PROTEIN; NUCLEAR PROTEIN; PROTEIN P21; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE; SMALL INTERFERING RNA; WEE1 PROTEIN, HUMAN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER PATIENT; COLORECTAL CANCER; CONTROLLED STUDY; DEPHOSPHORYLATION; DRUG EFFECT; DRUG POTENCY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VIVO STUDY; LUNG CANCER; MALIGNANT NEOPLASTIC DISEASE; MOUSE; NEUROBLASTOMA; NONHUMAN; PANCREAS CANCER; PROTEIN TARGETING; TUMOR GROWTH; VIRUS ONCOGENE; ANIMAL; DRUG EFFECTS; GENE SILENCING; GENETICS; LEUKEMIA, MYELOID, ACUTE; NUCLEOTIDE SEQUENCE; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; BASE SEQUENCE; CELL CYCLE PROTEINS; CELL LINE, TUMOR; GENE KNOCKDOWN TECHNIQUES; LEUKEMIA, MYELOID, ACUTE; MICE; NUCLEAR PROTEINS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS P21(RAS); PYRAZOLES; PYRIMIDINES; RNA, SMALL INTERFERING;

EID: 84920641027     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.149     Document Type: Article

References (50)

1. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 2003; 3: 11-22.
2. Bowen DT, Frew ME, Hills R, Gale RE, Wheatley K, Groves MJ et al. RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 years. Blood 2005; 106: 2113-2119.
3. Bacher U, Haferlach T, Schoch C, Kern W, Schnittger S. Implications of NRAS mutations in AML: a study of 2502 patients. Blood 2006; 107: 3847-3853.
4. Nakao M, Janssen JW, Seriu T, Bartram CR. Rapid and reliable detection of N-ras mutations in acute lymphoblastic leukemia by melting curve analysis using LightCycler technology. Leukemia 2000; 14: 312-315.
5. Ostrem JM, Peters U, Sos ML, Wells JA, Shokat KM. K-RAS. (G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 2013; 503: 548-551.
6. Lim SM, Westover KD, Ficarro SB, Harrison RA, Choi HG, Pacold ME et al. Therapeutic targeting of oncogenic K-RAS by a covalent catalytic site inhibitor. Angew Chem Int Ed Engl 2014; 53: 199-204.
7. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Franklin RA, Montalto G et al. RAS/Raf/MEK/ERK and PI3K/PTEN/AKT/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance. Oncotarget 2012; 3: 1068-1111.
8. Thoreen CC, Kang SA, Chang JW, Liu Q, Zhang J, Gao Y et al. An ATP-competitice mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem 2009; 284: 8023-8032.
9. Igarashi M, Nagata A, Jinno S, Suto K, Okayama H. Wee1+-like gene in human. Nature 1991; 353: 80-83.
10. cdc2-cyclin B complex by the human WEE1 tyrosine kinase. Science 1992; 257: 1955-1957.
11. cdc2 exclusively on Tyr15. EMBO J 1993; 12: 75-85.
12. Jin P, Gu Y, Morgan DO. Role of inhibitory CDC2 phosphorylation in radiation-induced G2 arrest in human cells. J Cell Biol 1996; 134: 963-970.
13. De Witt Hamer PC, Mir SE, Noske D, Van Noorden CJF, Wurdinger T. Wee1 kinase targeting combined with DNA-damaging cancer therapy catalyzes mitotic catastrophe. Clin Cancer Res 2011; 17: 4200-4207.
14. Hirai H, Arai T, Okada M, Nishibata T, Kobayashi M, Sakai N et al. MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil. Cancer Biol Ther 2010; 9: 514-522.
15. Rajeshkumar NV, De Oliveira E, Ottenhof N, Watters J, Brooks D, Demuth T et al. MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts. Clin Cancer Res 2011; 17: 2799-2806.
16. Liu Q, Chang JW, Wang J, Kang SA, Thoreen CC, Markhard A et al. Discovery of 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo[h] [1, 6]naphthyridin-2(1H)-one as a highly potent, selective mammalian target of rapamycin (mTOR) inhibitor for the treatment of cancer. J Med Chem 2010; 53: 7146-7155.
17. Matsuo Y, MacLeod RA, Uphoff CC, Drexler HG, Nishizaki C, Katayama Y et al. Two acute monocytic leukemia (AML-M5a) cell lines (MOLM13 and MOLM14) with interclonal phenotypic heterogeneity showing MLL-AF9 fusion resulting from an occult chromosome insertion, ins(11;9)(q23;p22p23). Leukemia 1997; 11: 1469-1477.
18. Kimbrel EA, Davis TN, Bradner JE, Kung AL. In vivo pharmacodynamic imaging of proteosome inhibition. Mol Imaging 2009; 8: 140-147.
19. Weisberg E, Manley PW, Breitenstein W, Bruggen J, Cowan-Jacob SW, Ray A et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005; 7: 129-141.
20. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22: 27-55.
21. Chen Z, Cheng K, Walton Z, Wang Y, Ebi H, Shimamura T et al. A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. Nature 2012; 483: 613-617.
22. Omholt K, Karsberg S, Platz A, Kanter L, Ringborg U, Hansson J. Screening of N-ras codon 61 mutations in paired primary and metastatic cutaneous melanomas: mutations occur early and persist throughout tumor progression. Clin Cancer Res 2002; 8: 3468-3474.
23. Arrington AK, Heinrich EL, Lee W, Duldulao M, Patel S, Sanchez J et al. Prognostic and predictive roles of KRAS mutation in colorectal cancer. Int J Mol Sci 2012; 13: 12153-12168.
24. Laghi L, Orbetegli O, Bianchi P, Zerbi A, Di Carlo V, Boland CR et al. Common occurrence of multiple K-RAS mutations in pancreatic cancers with associated precursor lesions and in biliary cancers. Oncogene 2002; 21: 4301-4306.
25. Pao W, Wang TY, Riely GJ, Miller VA, Pan Q, Ladanyi M et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2005; 2: e17.
26. Ward AF, Braun BS, Shannon KM. Targeting oncogenic RAS signaling in hematologic malignancies. Blood 2012; 120: 3397-3406.
27. Karp JE, Lancet JE, Kaufmann SH et al. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase I clinical-laboratory correlative trial. Blood 2001; 97: 3361-3369.
28. Downward J. Targeting RAS signaling pathways in cancer therapy. Nat Rev Cancer 2003; 3: 11-22.
29. Chresta CM, Davies BR, Hickson I, Harding T, Cosulich S, Chritchlow SE et al. AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo anti-tumor activity. Cancer Res 2010; 70: 288-298.
30. Banerji U, Aghajanian C, Raymond E, Kurzrock R, Blanco-Codesido M, Oelmann E et al. First results from a phase I trial of AZD8055, a dual mTORC1 and mTORC2 inhibitor. J Clin Oncol 2011; 29(suppl): abstract 3096.
31. Yu K, Shi C, Toral-Barza L, Lucas J, Shor B, Kim JE et al. Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE 125132, an ATP-com-petitive and specific inhibitor of mTORC1 and mTORC2. Cancer Res 2010; 70: 621-631.
32. Liu Q, Wang J, Kang SA, Thoreen CC, Hur W, Ahmed T et al. Discovery of 9 (6 aminopyridin-3 yl)-1 (3-(trifluoromethyl)phenyl)benzo[h][1, 6] naphthyridin 2(1H)-one (Torin 2) as a potent, selective, and orally available mammalian target of rapamycin (mTOR) inhibitor for treatment of cancer. J Med Chem 2011; 54: 1473-1480.
33. Liu Q, Xu C, Kirubakaran S, Zhang X, Hur W, Liu Y et al. Characterization of Torin 2, an ATP-competitive inhibitor of mTOR, ATM, and ATR. Cancer Res 2013; 73: 2574-2586.
34. Bracho-Valdes I, Moreno-Alvarez P, Valencia-Martinez I, Robles-Molina E, Chavez-Vargas L, Vazquez-Prado J. mTORC1-and mTORC2-interacting proteins keep their multifunctional partners focused. IUBMB Life 2011; 63: 896-914.
35. Zhang X, Tang N, Hadden TJ, AK Rishi. AKT, FoxO and regulation of apoptosis. Biochim Biophys Acta 2011; 1813: 1978-1986.
36. Proud CG. The eukaryotic initiation factor 4E-binding proteins and apoptosis. Cell Death Differ 2005; 12: 541-546.
37. Ducker GS, Atreya CE, Simko JP, Hom YK, Matli MR, Benes CH et al. Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors. Oncogene 2014; 33: 1590-1600.
38. Cassinelli G, Zuco V, Gatti L, Lanzi C, Zaffaroni N, Colombo D et al. Targeting the AKT kinase to modulate survival, invasiveness and drug resistance of cancer cells. Curr Med Chem 2013; 20: 1923-1945.
39. Castedo M, Perfettini JL, Roumier T, Kroemer G. Cyclin-dependent kinase-1: linking apoptosis to cell cycle and mitotic catastrophe. Cell Death Differ 2002; 9: 1287-1293.
40. Gwinn DM, Asara JM, Shaw RJ. Raptor is phosphorylated by cdc2 during mitosis. PLoS One 2010; 5: e9197.
41. Kreahling JM, Gemmer JY, Reed D, Letson D, Bui M, Altiok S. MK-1775 a selective Wee1 inhibitor, shows single-agent antitumor activity against sarcoma cells. Mol Cancer Ther 2012; 11: 174-182.
42. Guertin AD, Li J, Liu Y, Hurd MS, Schuller AG, Long B et al. Preclinical evaluation of the WEE1 inhibitor MK-1775 as single-agent anticancer therapy. Mol Cancer Ther 2013; 12: 1442-1452.
43. Russell MR, Levin K, Rader J, Belcastro L, Li Y, Martinez D et al. Combination therapy targeting the Chk1 and Wee1 kinases shows therapeutic efficacy in neuroblastoma. Cancer Res 2013; 73: 776-784.
44. Sarcar B, Kahali S, Prabhu AH, Shumway SD, Xu Y, Demuth T et al. Targeting radiation-induced G(2) checkpoint activation with the Wee-1 inhibitor MK-1775 in glioblastoma cell lines. Mol Cancer Ther 2011; 10: 2405-2414.
45. Bridges KA, Hirai H, Buser CA, Brooks C, Liu H, Buchholz TA et al. MK-1775, a novel Wee1 kinase inhibitor, radiosensitizes p53-defective human tumor cells. Clin Cancer Res 2011; 17: 5638-5648.
46. Aarts M, Sharpe R, Garcia-Murillas I, Gevensleben H, Hurd MS, Shumway SD et al. Forced mitotic entry of S-phase cells as a therapeutic strategy induced by inhibition of Wee1. Cancer Discov 2012; 2: 524-539.
47. Tibes R, Bogenberger JM, Chaudhuri L, Hagelstrom RT, Chow D, Buechel ME et al. RNAi screening of the kinome with cytarabine in leukemias. Blood 2012; 119: 2863-2872.
48. Ramamoorthy K, Ramesh P, Al Bahar S. Primary treatment of acute myeloid leukemia (non M3) in elderly: a review. Gulf J Oncolog 2008; 4: 19-26.
49. Yoshida T, Tanaka S, Mogi A, Shitara Y, Kuwano H. The clinical significance of cyclin B1 and Wee1 expression in non-small-cell lung cancer. Ann Oncol 2004; 15: 252-256.
50. Magnussen GI, Holm R, Emilsen E, Rosnes AK, Slipicevic A, Florenes VA. High expression of Wee1 is associated with poor disease-free survival in malignant melanoma: potential for targeted therapy. PLoS One 2012; 7: e38254.